Torthaí cuardaigh - Falchook, Gerald S

ACTR-35. MOLECULAR MATCHMAKING: EFFICACY OF EARLY CLINICAL TRIALS GUIDED BY NEXT-GENERATION SEQUENCING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME de réir Leary, Jacob, Pearlman, Michael, Falchook, Gerald

Faigh an téacs iomlán Faigh an téacs iomlán

Dabrafenib for treatment of BRAF-mutant melanoma de réir Kainthla, Radhika, Kim, Kevin B, Falchook, Gerald S

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers de réir Nguyen, Martin V., Loof, Lydia, Falchook, Gerald S.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

HER2-Amplified Salivary Duct Carcinoma: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment de réir Falchook, Gerald S., Lippman, Scott M., Bastida, Christel C., Kurzrock, Razelle

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

DCVax®- DIRECT: autologous activated dendritic cells for image guided intra-tumoral vaccination in patients with solid tumors - a phase I/II clinical trial in progress de réir Subbiah, Vivek, Murthy, Ravi, Hosing, Chitra, Kaur, Indresh, Falchook, Gerald, Bosch, Marnix

Faigh an téacs iomlán Faigh an téacs iomlán

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer de réir Patel, Manish R., Falchook, Gerald S., Hamada, Kensuke, Makris, Lukas, Bendell, Johanna C.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Non-Small Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment de réir Falchook, Gerald S., Janku, Filip, Tsao, Anne S., Bastida, Christel C., Stewart, David J., Kurzrock, Razelle

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 de réir Falchook, Gerald S., Leidner, Rom, Stankevich, Elizabeth, Piening, Brian, Bifulco, Carlo, Lowy, Israel, Fury, Matthew G.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors de réir Naing, Aung, Fu, Siqing, Zinner, Ralph G., Wheler, Jennifer J., Hong, David S., Arakawa, Kazuhito, Falchook, Gerald S., Kurzrock, Razelle

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes de réir El-Osta, Hazem, Falchook, Gerald, Tsimberidou, Apostolia, Hong, David, Naing, Aung, Kim, Kevin, Wen, Sijin, Janku, Filip, Kurzrock, Razelle

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Merkel Cell Polyomavirus and HPV-17 Associated with Cutaneous Squamous Cell Carcinoma Arising in a Melanoma Patient Treated with a BRAF Inhibitor de réir Falchook, Gerald S., Rady, Peter, Hymes, Sharon, Nguyen, Harrison P., Tyring, Stephen K., Prieto, Victor G., Hong, David S., Kurzrock, Razelle

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors de réir Papadopoulos, Kyriakos P., Lakhani, Nehal, Falchook, Gerald S., Riley, Gosia, Baeck, Johan, Brown, Karen S., Gordon, Gilad, Le, Lidya, Wang, Judy S.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Phase I Clinical Trials in 85 Patients with Gynecologic Cancer: The M. D. Anderson Cancer Center Experience de réir Moroney, John, Wheler, Jennifer, Hong, David, Naing, Aung, Falchook, Gerald, Bodurka, Diane, Coleman, Robert, Lu, Karen, Xiao, Lianchun, Kurzrock, Razelle

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study de réir Falchook, Gerald, Kurzrock, Razelle, Gouw, Launce, Hong, David, McGregor, Kimberly A., Zhou, Xiaofei, Shi, Hongliang, Fingert, Howard, Sharma, Sunil

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical... de réir Subbiah, Ishwaria M., Tang, Chad, Rao, Arvind, Falchook, Gerald S., Subbiah, Vivek, Tsimberidou, Apostolia M., Karp, Daniel, Kurzrock, Razelle, Hong, David S.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose de réir Xiong, Wenyuan, Friese‐Hamim, Manja, Johne, Andreas, Stroh, Christopher, Klevesath, Manfred, Falchook, Gerald S., Hong, David S., Girard, Pascal, El Bawab, Samer

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours de réir Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience de réir El-Osta, Hazem, Hong, David, Wheler, Jennifer, Fu, Siqing, Naing, Aung, Falchook, Gerald, Hicks, Marshall, Wen, Sijin, Tsimberidou, Apostolia M., Kurzrock, Razelle

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers de réir Janku, Filip, Lee, J. Jack, Tsimberidou, Apostolia M., Hong, David S., Naing, Aung, Falchook, Gerald S., Fu, Siqing, Luthra, Rajyalakshmi, Garrido-Laguna, Ignacio, Kurzrock, Razelle

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Phase I Study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors de réir Hong, David, Said, Rabih, Falchook, Gerald, Naing, Aung, Moulder, Stacy, Tsimberidou, Apostolia-Maria, Galluppi, Gerald, Dakappagari, Naveen, Storgard, Chris, Kurzrock, Razelle, Rosen, Lee S.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán